Scribe Therapeutics, Inc.
No enriched coverage for $SCTX in the last 7 days.
Eli Lilly and Company disclosed a 7.36% stake in Scribe Therapeutics, Inc. common stock. The position combines shares from a July 10, 2026 conversion of an 8% convertible note and 333,333 shares bought in Scribe’s July 23, 2026 IPO, according to a Schedule 13D filed on Jul. 30, 2026. The move links a major pharmaceutical company to Scribe following its IPO and signals potential engagement.
AH Bio Fund II, L.P. purchased 333,333 indirectly-held shares of Scribe Therapeutics, Inc. (SCTX) at $15.00 ($5.00M total) on 2026-07-27.
GORDON CARL L purchased 1,000,000 indirectly-held shares of Scribe Therapeutics, Inc. (SCTX) at $15.00 ($15.00M total) on 2026-07-27.
Recent SCTX coverage spans insider activity, financial news and ipo.
In the last 30 days, SCTX insiders filed 9 SEC Form 4 transactions — 9 purchases ($71.3M) and no sales. The most active reporter was Aghazadeh Behzad with 3 filings.
A major pharma disclosed a meaningful stake and signals potential engagement, which can re-rate perceived strategic optionality for Scribe.
This is a disclosed insider-related accumulation by a 10% owner via an open-market purchase, with no 10b5-1 plan cited.
The filing is a fresh insider buy datapoint, but it is not a fundamental catalyst like earnings, guidance, or a deal.
A large director-linked open-market purchase signals increased insider confidence, but it is indirect and not a 10b5-1 plan.
The filing is a large insider buy, but it is not tied to new fundamentals or guidance in the text.
alphai scores every news story that mentions SCTX with an AI model for sentiment and relevance, and aggregates insider trades from Scribe Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Eli Lilly and Company disclosed a 7.36% stake in Scribe Therapeutics, Inc. common stock. The position combines shares from a July 10, 2026 conversion of an 8% convertible note and 333,333 shares bought in Scribe’s July 23, 2026 IPO, according to a Schedule 13D filed on Jul. 30, 2026. The move links a major pharmaceutical company to Scribe following its IPO and signals potential engagement.
4 min readAH Bio Fund II, L.P. purchased 333,333 indirectly-held shares of Scribe Therapeutics, Inc. (SCTX) at $15.00 ($5.00M total) on 2026-07-27.
2 min readGORDON CARL L purchased 1,000,000 indirectly-held shares of Scribe Therapeutics, Inc. (SCTX) at $15.00 ($15.00M total) on 2026-07-27.
1 min readORBIMED ADVISORS LLC purchased 1,000,000 indirectly-held shares of Scribe Therapeutics, Inc. (SCTX) at $15.00 ($15.00M total) on 2026-07-27.
1 min readAghazadeh Behzad purchased 2,391,238 indirectly-held shares of Scribe Therapeutics, Inc. (SCTX) at an average of $15.16 ($15.00–$22.31, $36.26M total) across 3 trades over 2026-07-24 to 2026-07-28.
1 min readLucas Svetlana (Chief Business Officer) purchased 3,000 indirectly-held shares of Scribe Therapeutics, Inc. (SCTX) at $15.00 on 2026-07-23.
1 min readParrot David (Chief Financial Officer) purchased 2,666 indirectly-held shares of Scribe Therapeutics, Inc. (SCTX) at $15.00 across 2 trades on 2026-07-23.
1 min readScribe Therapeutics raised about $129M in its IPO, selling 8.58M shares at $15 each, above earlier projections, and will start trading Friday on Nasdaq as SCTX. The article notes biotech IPO activity in 2026 and compares Scribe’s smaller, earlier-stage gene-editing focus to recent larger offerings.
3 min readAccording to ARK’s published trades for July 24, 2026, ARK sold 718,303 shares of Figma Inc (FIG) for about $14.37M across ARKK and ARKW. It bought 361,253 shares of Scribe Therapeutics (SCTX) for about $5.42M and added to Compass Pathways (CMPS) for about $1.25M. It also sold ATAI Beckley (ATAI) and bought Kodiak AI (KDK), Pony AI (PONY), X-Energy (XE), and others.
3 min readScribe Therapeutics (SCTX), a gene therapy developer backed by Sanofi (SNY) and Eli Lilly (LLY), jumped nearly 50% in its first public trading session following an upsized IPO on Friday. The article links the collaborators to Scribe’s launch and highlights the initial share-price move.
1 min read
